Dublin, December 22, 2021 (GLOBE NEWSWIRE) – The “Global Parenteral Nutrition Market by Nutrient Type (Single-Dose Amino Acid Solution, Parenteral Lipid Emulsion, Carbohydrates, Trace Elements, and Vitamins and Minerals), by Regional Outlook, COVID-19 Report on Effect Analysis and Forecast , 2021-2027 “Report was added to ResearchAndMarkets.com to offer.
The global parenteral nutrition market is expected to reach US $ 10.9 billion by 2027, increasing with market growth of 8.1% CAGR over the forecast period.
Parenteral nutrition (parenteral nutrition) or intravenous nutrition provides liquid nutrients such as proteins, vitamins, fats, electrolytes, minerals and carbohydrates. It is part of specialized nutritional therapy that provides nutritional support to patients who are unable to properly use their gastrointestinal tract. It is extremely helpful in eliminating malnutrition and maintaining fluid, energy, and strength levels. For this reason, it is widely used in patients suffering from cancer, hydration, Crohn’s disease, ischemic bowel disease, short bowel syndrome, and abnormal bowel function.
The development of the parenteral nutrition market is expected to be driven by the rise in child malnutrition, mainly in emerging and underdeveloped countries around the globe. In addition, the need for parenteral nutrition (parenteral nutrition) to properly balance amino acids, lipids, vitamins, minerals, and other nutrients is expected to create good growth prospects for the growth of the parenteral nutrition market.
The introduction of parenteral nutrition is expected to be a driving force as it reduces the risk of underdevelopment and infection. Newborns with a very low birth weight (VLBW) have a high demand for products for parenteral nutrition due to the low possibility of enteral nutrition (EN). In addition, increasing acceptance of parenteral nutrition for premature infants, which leads to better neurological growth, increases intrauterine nutrient deposition and reduces the likelihood of complications, thereby improving their chances of survival.
COVID-19 impact analysis
The outbreak of the COVID-19 pandemic has significantly increased the adoption rate of parenteral nutrition in order to provide the body with the food and fluids necessary for a quick and safe recovery. In addition, it is expected that the increasing acceptance of the administration of food by the parenteral medium compared to enteral nutrition in the patients suffering from COVID-19 to meet the necessary nutritional needs, an increasing nutrient intake and a decreasing risk of infection will accelerate the demand and growth of the entire parenteral nutrition market in the coming years.
In addition, the increasing adoption of these formulations among clinicians are some of the factors driving the development of the global parenteral nutrition market to help patients achieve their target nutritional intake, improve recovery, and reduce hospital stays.
Market growth factors:
The rise in the rate of malnutrition in the world population
In addition, the governments of numerous countries are taking various initiatives to reduce the growing burden of malnutrition and thereby increase the need for intravenous feeding. Various government organizations such as Action against Hunger, Food4Africa, Heifer International and the World Health Organization are ready to take new initiatives aimed at providing better treatment to malnourished people.
Higher prevalence of various chronic diseases
Different types of diseases such as head and neck cancer, esophageal cancer, Crohn’s disease, ulcerative colitis, stomach cancer, and larynx cancer can affect patients’ oral feeding. Due to their increasing occurrence, the global parenteral nutrition market is expected to expand in the coming years.
Market-inhibiting factor:
Increasing inclination towards enteral nutrition
The preference for enteral nutrition is steadily increasing among patients around the world. Health professionals generally suggest enteral nutrition versus parenteral nutrition. This is because it is less expensive, easy to administer, and has fewer complications. In addition, enteral nutrition enables better and more effective nutrient absorption and supports the body’s natural healing process by stimulating intestinal blood flow.
Outlook on the nutrient type
Based on the nutrient type, the market is divided into Single Dose Amino Acid Solution, Parenteral Lipid Emulsion, Carbohydrates, Trace Elements, and Vitamins and Minerals. The parenteral lipid emulsions segment is expected to show the fastest growth rate in the forecast period. The increasing incidence of malnutrition in hospitals is the main factor driving the demand for parenteral lipid emulsions as they provide patients with non-protein calories and essential fatty acids, reduce inflammation, and improve metabolic and clinical outcomes. In addition, the segment’s demand in hospitals is expected to be boosted by the increasing demand from critically ill patients and the high rates of chronic diseases such as inflammatory bowel disease, cancer and diabetes.
Regional outlook
Based on the regions, the market is segmented into North America, Europe, Asia-Pacific, and Latin America, the Middle East and Africa. Asia Pacific is expected to show the fastest growth rate over the forecast period. The regional market is expected to be boosted by economic growth in various countries such as India, Japan and China and the supporting government initiatives along with favorable reimbursement policies and the growth of the healthcare industry. In addition, the rise in the incidence of chronic diseases, increased awareness of the benefits of nutrient types, and growing numbers of parenteral nutrition users in some of the region’s emerging markets are expected to create new growth opportunities for operating players in the regional parenteral nutrition market in the forecast years.
The market research report covers the analysis of the key market players. Key companies featured in the report include Vifor Pharma Management Ltd., Baxter International, Inc., Allergan PLC (AbbVie), B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Grifols SA, Pfizer, Inc., ICU Medical, Inc., Anhui Medipharm Co., Ltd. and Aculife Healthcare Private Limited.
Key topics covered:
Chapter 1. Market Scope and Methodology
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Effects of COVID-19
2.1.1.2 Market composition and scenario
2.2 Key factors influencing the market
2.2.1 Market drivers
2.2.2 Market Restrictions
Chapter 3. Global Parenteral Nutrition Market by Nutrient Type
3.1 Global Single Dose Amino Acid Solution Market by Regions
3.2 Global Parenteral Lipid Emulsions Market by Regions
3.3 Global Carbohydrate Market by Region
3.4 Global Trace Elements Market by Region
3.5 Global Other Nutrient Types Market by Region
Chapter 4. Global Parenteral Nutrition Market by Region
Chapter 5. Company Profiles
5.1 Vifor Pharma Management AG
5.1.1 Company overview
5.1.2 Financial analysis
5.1.3 Research and development costs
5.2 Baxter International, Inc.
5.2.1 Company overview
5.2.2 Financial analysis
5.2.3 Regional analysis
5.2.4 Research and development costs
5.2.1 Latest strategies and developments:
5.2.1.1 Partnerships, collaborations and agreements:
5.2.1.2 Product launches and product extensions:
5.2.1.3 Approvals and trails:
5.3 Allergan PLC (AbbVie)
5.3.1 Company overview
5.3.2 Financial analysis
5.3.3 Regional analysis
5.3.4 Research and development costs
5.4 B. Braun Melsungen AG
5.4.1 Company overview
5.4.2 Financial analysis
5.4.3 Segment and regional analysis
5.4.4 Research and development costs
5.5 Fresenius SE & Co. KGaA
5.5.1 Company overview
5.5.2 Financial analysis
5.5.3 Segment and regional analysis
5.5.4 Research and development costs
5.6 Grifols SA
5.6.1 Company overview
5.6.2 Financial analysis
5.6.3 Segment and regional analysis
5.6.4 Research and development costs
5.7 Pfizer, Inc.
5.7.1 Company overview
5.7.2 Financial analysis
5.7.3 Regional analysis
5.7.4 Research and development costs
5.8 ICU Medical, Inc.
5.8.1 Company overview
5.8.2 Latest strategies and developments:
5.8.2.1 Partnerships, collaborations and agreements:
5.9 Anhui Medipharm Co., Ltd.
5.9.1 Company overview
5.10. Aculife Healthcare Private Limited
5.10.1 Company overview
Please visit https://www.researchandmarkets.com/r/pj61f2 for more information on this report
